Middle East and Africa Blau Syndrome Market - Industry Trends and Forecast to 2027

Report ID: | Publihed: 07-Jan-2020 | No of Pages: 80


USD 3995
USD 5795

Publish Date:


Total pages:


Middle East & Africa Blau syndrome market is projected to register a substantial CAGR of 8.3% in the forecast period of 2020 to 2027. The new market report contains data for the historic year 2018, the base year of calculation is 2019 and the forecast period is 2020 to 2027.
Market Segmentation:
Middle East and Africa Blau Syndrome Market, By Type (Treatment and Diagnosis), Therapeutic Areas (Skin Rash, Inflammation), Route of Administration (Oral, Parenteral, Topical, Others), End User (Hospitals, Diagnostic Centers, Clinics, Home Healthcare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others), Country (South Africa, Saudi Arabia, U.A.E., Israel, Kuwait, Egypt and rest of Middle East and Africa) Industry Trends and Forecast to 2027

Some of the major factors contributing to the growth of Middle East and Africa Blau syndrome market are:

• High demand of disease specific treatment
• High adoption of biological therapies

Market Players:

The key market players for Middle East and Africa Blau syndrome market are listed below:

• Hikma Pharmaceuticals PLC
• Novartis AG
• Pfizer Inc.
• AbbVie Inc.
• Janssen Pharmaceuticals, Inc. (a subsidiary of Johnson & Johnson Services Inc.)
• Mylan N.V.
• Invitae Corporation
• Swedish Orphan Biovitrum AB
• F. Hoffmann-La Roche Ltd

Report Subsumes the following

Competitors Analysis Go To Market Strategies
Regional Coverage with precise Market Numbers Global Impact post Covid-19
Market Penetration Strategies Granular breakdown By Type and By Application.